Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with <i>Mycoplasma pneumoniae</i> Pneumonia: A Systematic Review and Meta-Analysis of Efficacy and Safety

<div>Graph (a) and summary (b) for risk of selection bias. The low risk and unclear risk of bias was illustrated by signs <svg height="7.35473pt" id="M2" style="vertical-align:-0.3499303pt" version="1.1" viewbox="-0.0498162 -7.0048 7.75925 7.35473" width="7.75925pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M535 230V280H323V490H265V280H52V230H265V-3H323V230H535Z"></path></g></svg> and <span class="nowrap"><svg height="8.93363pt" id="M3" style="vertical-align:-0.1802902pt" version="1.1" viewbox="-0.0498162 -8.75334 5.04511 8.93363" width="5.04511pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M219 216C189 242 172 263 172 297C172 345 252 390 284 417C318 445 332 470 332 505C332 587 255 665 171 665H170C154 665 110 654 79 627C64 615 58 605 58 591C58 567 86 547 99 547C110 547 150 601 213 601C250 601 273 581 273 546C273 504 211 463 174 435C111 387 90 357 90 323C90 262 163 207 201 193L219 216ZM184 -12C216 -12 240 11 240 46C240 78 216 103 185 103S130 78 130 46C130 11 154 -12 184 -12Z"></path></g></svg>,</span> respectively.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with <i>Mycoplasma pneumoniae</i> Pneumonia: A Systematic Review and Meta-Analysis of Efficacy and Safety 

Figure 2 | Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with Mycoplasma pneumoniae Pneumonia: A Systematic Review and Meta-Analysis of Efficacy and Safety 